Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
NAUT
Nautilus Biotechnology, Inc.
The hardware/assay suite functions as diagnostic-type equipment for proteomics analyses.
|
$252.61M |
$2.00
+9.56%
|
|
NGNE
Neurogene Inc.
NGNE directly develops gene therapy candidates (NGN-401) and uses a gene therapy platform, matching Biotech - Gene Therapy.
|
$250.47M |
$17.59
-2.60%
|
|
MPAA
Motorcar Parts of America, Inc.
MPAA markets and sells diagnostic equipment, such as the JBT-1 Bench Top tester.
|
$249.06M |
$13.04
+1.36%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$247.92M |
$2.73
-3.02%
|
|
PROF
Profound Medical Corp.
Profound's flagship TULSA-PRO is a surgical device used for MR-guided prostate tissue ablation.
|
$247.04M |
$8.27
-0.84%
|
|
SNFCA
Security National Financial Corporation
Death care services (cemetery and mortuary) are a direct service offering aligned with healthcare services and facilities.
|
$243.98M |
$9.41
+0.21%
|
|
MGRM
Monogram Orthopaedics, Inc.
Direct product category: Monogram's system is a surgical device used in operating rooms for orthopedic procedures.
|
$243.79M |
$6.00
|
|
STXS
Stereotaxis, Inc.
Catheter-based cardiology devices (ablation/catheters) are a core direct product, fitting Cardiology Devices.
|
$242.95M |
$2.67
-4.12%
|
|
GNFT
Genfit S.A.
GENFIT's ELAFIBRONOR in Primary Biliary Cholangitis (PBC) represents a core liver-disease therapeutic offering.
|
$242.48M |
$4.90
+1.03%
|
|
WW
WW International, Inc.
WW operates WW Clinic and integrated weight health services, including clinical care delivery.
|
$238.89M |
$23.92
+0.89%
|
|
SLN
Silence Therapeutics plc
Silence Therapeutics directly develops RNA interference therapeutics (siRNA) as its core product modality.
|
$237.82M |
$5.04
-9.35%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Lead oncology candidate MIE-101 defines CPMV's core product focus in cancer therapy.
|
$236.42M |
$0.59
|
|
OWLT
Owlet, Inc.
Owlet sells FDA-cleared Medical Devices & Biometrics (Dream Sock and BabySat) with wearable biosensing capabilities.
|
$234.19M |
$13.73
+0.99%
|
|
OABI
OmniAb, Inc.
OmniAb's core offering is the Antibody Discovery Platform enabling rapid generation of human antibodies through engineered transgenic animals and associated discovery tools.
|
$233.13M |
$1.92
|
|
ELMD
Electromed, Inc.
Electromed manufactures the SmartVest Clearway airway clearance medical device, fitting the Medical Devices & Biometrics investable theme.
|
$232.36M |
$27.99
-1.17%
|
|
SNWV
SANUWAVE Health, Inc.
SANUWAVE directly manufactures and markets medical devices (UltraMIST and related wound-care technology) and biometrics for patient care.
|
$232.02M |
$27.23
-1.87%
|
|
SMTI
Sanara MedTech Inc.
bone fusion/orthopedic implants (BiFORM, ALLOCYTE Plus) and associated bone void filler (OsStic) place the company in Orthopedic Devices.
|
$230.66M |
$25.48
-1.66%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$228.40M |
$1.50
+0.67%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
AVIM therapy is an implantable cardiac stimulation-based treatment for hypertension, aligning with Cardiology Devices.
|
$227.69M |
$4.24
+1.56%
|
|
QNCX
Quince Therapeutics, Inc.
Lead asset targets Ataxia-Telangiectasia, a rare disease, aligning Quince with the Rare Diseases biotech investment theme.
|
$226.67M |
$4.28
-2.73%
|
|
ASMB
Assembly Biosciences, Inc.
Assembly Biosciences develops small-molecule antiviral therapeutics, including HSV helicase-primase inhibitors, HDV entry inhibitors, HBV capsid assembly modulators, and NNPI programs.
|
$225.33M |
$29.27
-2.14%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$222.27M |
$4.63
+3.69%
|
|
CGEN
Compugen Ltd.
Company focus and programs are centered in oncology/immuno-oncology, qualifying under Biotech - Oncology.
|
$220.74M |
$2.37
+12.09%
|
|
OMI
Owens & Minor, Inc.
OMI sells and distributes medical devices and biometric equipment for home healthcare and clinical use.
|
$216.57M |
$2.80
|
|
NVCT
Nuvectis Pharma, Inc.
Nuvectis' lead asset NXP900 is a cancer-targeting therapy (SRC/YES1 kinase inhibitor), placing the company in Biotech - Oncology.
|
$215.87M |
$8.55
+0.23%
|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Zentalis is a biotech company focused on oncology therapies, centered on cancer indications with their lead asset azenosertib.
|
$213.52M |
$2.96
-6.49%
|
|
FENC
Fennec Pharmaceuticals Inc.
Direct product in oncology/supportive care with FDA-approved PEDMARK therapy for cisplatin-induced ototoxicity.
|
$210.13M |
$7.74
+2.45%
|
|
VYGR
Voyager Therapeutics, Inc.
Voyager’s core offerings are gene therapies and gene-delivery platforms, including APOE and tau-targeted approaches.
|
$208.56M |
$3.77
-1.44%
|
|
PRE
Prenetics Global Limited
Insighta's FRAGMA liquid biopsy enables multi-cancer early detection.
|
$208.18M |
$15.77
+6.05%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
CRGX's core offerings are oncology CAR-T therapies (firi-cel, CRG-23), placing it in Biotech - Oncology.
|
$206.13M |
$4.47
|
Showing page 21 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
